{
    "nctId": "NCT02858856",
    "briefTitle": "Clinical Trial of Sipjeondaebo-tang on Fatigue of Breast Cancer Patients",
    "officialTitle": "Sipjeondaebo-tang for Alleviating Fatigue Measured by Brief Fatigue Inventory and EORTC-QLQ-C30, BR23 Score Change Among Patients With Breast Carcinoma Receiving Chemotherapy",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 48,
    "primaryOutcomeMeasure": "Brief Fatigue Inventory change",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* men and women aged over 18 years\n* patients who have histologically or cytologically confirmed breast tumor\n* patients who applicable AC(doxorubicin + cyclophosphamide)\n* ECOG score 0 to 2\n\nExclusion Criteria:\n\n* patient impossible to orally intake\n* patient with dementia, delirium and depression\n* patient suffering from diseases like chronic hepatitis B, C or hepatocirrhosis\n* severe liver disability (3-fold the normal high range value for ALT, AST)\n* patient who has diabetes not controlled by diet, hypertension, hyperthyroidism,\n* severe systemic disease\n* use of other investigational products within the past 30 days\n* hypersensitivity to investigational product\n* others who are judged not to be appropriate to study",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}